Literature DB >> 28849794

Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapy.

John R Counsell, Zeinab Asgarian, Jinhong Meng, Veronica Ferrer, Conrad A Vink, Steven J Howe, Simon N Waddington, Adrian J Thrasher, Francesco Muntoni, Jennifer E Morgan, Olivier Danos.   

Abstract

This corrects the article DOI: 10.1038/srep44775.

Entities:  

Year:  2017        PMID： 28849794      PMCID： PMC7365309          DOI： 10.1038/srep46880

Source DB:  PubMed          Journal:  Sci Rep        ISSN： 2045-2322            Impact factor:   4.379


10.1038/srep44775 This article was published twice in error during a change in production systems. The publisher apologizes to the authors and readers for the error. When citing this work, please refer to the original version.[1]
  1 in total

1.  Lentiviral vectors can be used for full-length dystrophin gene therapy.

Authors:  John R Counsell; Zeinab Asgarian; Jinhong Meng; Veronica Ferrer; Conrad A Vink; Steven J Howe; Simon N Waddington; Adrian J Thrasher; Francesco Muntoni; Jennifer E Morgan; Olivier Danos
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379
  1 in total
  1 in total

1.  Production of lentiviral vectors using novel, enzymatically produced, linear DNA.

Authors:  Rajvinder Karda; John R Counsell; Kinga Karbowniczek; Lisa J Caproni; John P Tite; Simon N Waddington
Journal:  Gene Ther       Date:  2019-01-14       Impact factor: 5.250
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.